A team from the Royal Marsden in Sutton have pioneered a research project called MonarchE.
They found that adding a drug called abemaciclib to standard hormone therapy reduced reoccurrence in 25% of patients.
Around 70% of breast cancer patients have hormone receptor positive tumours with a higher risk of relapsing in two years.